SEC Form 4 · accession 0001470831-26-000836

BridgeBio Pharma, Inc. · BBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Neil Kumar

Officer — Chief Executive Officer · Director

Period of report

Aug 16, 2026

Accepted (ET)

Aug 18, 2026 · 6:02 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001743881

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 16, 2026	M	33,544	—	A	276,871	D
Common Stock^F1	Aug 16, 2026	M	19,599	—	A	296,470	D
Common Stock^F1	Aug 16, 2026	M	11,554	—	A	308,024	D
Common Stock^F1	Aug 16, 2026	M	6,520	—	A	314,544	D
Common Stock^F2	Aug 16, 2026	F	36,237	$79.86	D	278,307	D
Common Stock^F3	holding	—	—		—	515,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock^F4,F3	holding	—	—		—	3,568,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock^F4,F5	holding	—	—		—	750,000	I	By NK 2026 GRAT

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F6	—	Aug 16, 2026	M	33,544	D	—	—	Common Stock	33,544	67,088	D
Restricted Stock Units^F1,F7	—	Aug 16, 2026	M	19,599	D	—	—	Common Stock	19,599	117,596	D
Restricted Stock Units^F1,F8	—	Aug 16, 2026	M	11,554	D	—	—	Common Stock	11,554	115,538	D
Restricted Stock Units^F1,F9	—	Aug 16, 2026	M	6,520	D	—	—	Common Stock	6,520	91,274	D

Explanation of responses

F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs.
F3The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4Reflects a prior transfer of 750,000 shares of Common Stock from the Kumar Haldea Revocable Trust to the NK 2026 GRAT. The transfer constituted only a change in form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
F5These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
F6The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F7The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F8The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F9The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.